Lightricks’ LTX Studio, the AI Visual Storytelling Platform, Now Open to All
20.8.2024 15:01:00 EEST | Business Wire | Press release
Lightricks, the AI innovators behind Facetune, Videoleap, Photoleap and Popular Pays, announced today that LTX Studio beta, the first AI-driven storyboarding and prototyping platform, is now open to the public. The platform, designed for creative film and marketing professionals, offers real-time, intuitive generative and editing solutions. This announcement includes new features that push the boundaries of visual storytelling, such as increased character and frame control and multi-user collaboration.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240820994937/en/
The LTX Studio platform integrates proprietary AI research from Lightricks engineers with the latest licensed and open-source generative AI models, redefining the creative process. It streamlines video production planning and execution, empowering a wide range of creative professionals—from individual filmmakers to large production companies and advertising agencies—to develop, visualize, storyboard, and pitch their creative concepts into fully crafted film and video projects with unprecedented efficiency and control.
“Releasing LTX Studio to everyone demonstrates our ongoing commitment to the future of video creation through innovative AI-driven tools and our belief in generative AI as a powerful market changer," said Zeev Farbman, CEO and co-founder of Lightricks. “We’ve worked closely with our design partners and creator community to ensure our platform meets their diverse needs better than anything else on the market. We remain committed to exploring new technology and enhancing LTX Studio’s capabilities.”
LTX Studio’s suite of AI features has been refined based on technical and creative feedback from our creative community of more than 35,000 members. The latest updates focus on:
- Enhanced Collaboration: The new Collaboration feature enables creative teams to work together more efficiently with live edit views. LTX Studio plans to release additional collaborative tools, such as commenting and suggestion capabilities, soon.
- Character Acting: LTX Studio now syncs realistic voices with lip movements for any character, allowing users to customize facial gestures and dialogues by referencing real human videos. Users can generate voice from text using AI or upload their original voice files. Future updates will include voice switching for character dialogue and complete scene editing with dialogues.
- Generation Control: Users can now enjoy more control and accuracy in creating their wanted frames and desired motion. Frame Creator lets users craft frames using prompts and scribbles. Keyframe Control generates frames between defined start and end points.
Case Study: Recently, financial services company eToro used LTX Studio to create an AI-generated advertisement that aired during the Paris Olympics. This showcased LTX Studio’s ability to produce high-quality, realistic video content, demonstrating how brands can easily leverage LTX Studio to create compelling visual stories.
Pricing: LTX Studio now offers a tiered pricing model. Users can experience the platform for free with limited generative AI capability, or select from a range of plans based on their monthly generative time needs. Custom plans with premium features are available for enterprises and larger organizations and teams.
Lightricks is embarking on a prolific roadmap for LTX Studio leading into 2025, focusing on leveraging AI to innovate the visual storytelling experience and fuel creativity for professional creators globally. To experience LTX Studio today, join at LTX.Studio.
About Lightricks
Lightricks, an AI-first company, is revolutionizing how visual content is created. With a mission to bridge the gap between imagination and creation, Lightricks is dedicated to bringing cutting-edge technology to the creative and business spaces.
Our AI photo and video generation models, which power our apps and platforms including Facetune, Photoleap, Videoleap, and LTX Studio, allow creators and brands to leverage the latest research breakthroughs, offering endless control over their creative potential. Our influencer marketing platform, Popular Pays, provides creators the ability to monetize their work and offers brands opportunities to scale their content through tailored creator partnerships.
Founded in 2013, Lightricks is backed by prominent investors including Goldman Sachs Growth Equity, Insight Partners and Viola Ventures, who share Lightricks’ enduring commitment to driving the future of content creation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240820994937/en/
Contacts
Olivia Knecht
lightricks@clarity.global
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom